Ocular Therapeutix (NASDAQ:OCUL) Shares Up 6.6% – Still a Buy?

Posted by Stanley Muller on Jul 7th, 2026

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report)’s stock price rose 6.6% during mid-day trading on Tuesday . The company traded as high as $10.23 and last traded at $10.2990. 674,177 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 4,594,744 shares. The stock had previously closed at $9.66.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target (up from $21.00) on shares of Ocular Therapeutix in a research report on Thursday, June 18th. Robert W. Baird lifted their price objective on Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Chardan Capital lifted their price target on Ocular Therapeutix from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Tuesday, April 21st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.11.

View Our Latest Stock Analysis on OCUL

Ocular Therapeutix Stock Up 4.5%

The business has a 50-day moving average of $9.12 and a 200 day moving average of $9.58. The company has a market capitalization of $2.21 billion, a PE ratio of -6.91 and a beta of 0.88. The company has a debt-to-equity ratio of 0.12, a current ratio of 14.81 and a quick ratio of 14.73.

Insider Activity

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total transaction of $173,479.20. Following the sale, the insider directly owned 2,597,170 shares of the company’s stock, valued at $21,296,794. The trade was a 0.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 28,999 shares of company stock worth $237,792. 3.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Ocular Therapeutix

Institutional investors have recently bought and sold shares of the stock. Cantor Fitzgerald L. P. purchased a new stake in shares of Ocular Therapeutix in the third quarter valued at $2,360,000. Avoro Capital Advisors LLC grew its holdings in Ocular Therapeutix by 38.5% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after purchasing an additional 2,850,000 shares during the last quarter. Empire Life Investments Inc. raised its position in Ocular Therapeutix by 115.0% in the 4th quarter. Empire Life Investments Inc. now owns 540,115 shares of the biopharmaceutical company’s stock worth $6,557,000 after purchasing an additional 288,853 shares during the period. Assenagon Asset Management S.A. raised its position in Ocular Therapeutix by 1,261.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 620,814 shares of the biopharmaceutical company’s stock worth $7,537,000 after purchasing an additional 575,214 shares during the period. Finally, Prescott Group Capital Management L.L.C. bought a new stake in Ocular Therapeutix in the fourth quarter worth about $3,800,000. 59.21% of the stock is currently owned by institutional investors.

About Ocular Therapeutix

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.